NeoGenomics (NASDAQ:NEO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of NeoGenomics (NASDAQ:NEOGet Rating) in a report released on Thursday morning. The firm issued a hold rating on the medical research company’s stock.

A number of other research firms also recently issued reports on NEO. Morgan Stanley increased their price objective on shares of NeoGenomics from $17.00 to $18.00 and gave the company an equal weight rating in a research note on Friday, February 24th. Needham & Company LLC increased their price objective on shares of NeoGenomics from $15.00 to $21.00 and gave the company a buy rating in a research note on Friday, February 24th. Raymond James raised their target price on shares of NeoGenomics from $12.00 to $19.00 and gave the company an outperform rating in a research note on Friday, February 24th. Cowen raised their target price on shares of NeoGenomics from $14.00 to $20.00 and gave the company an outperform rating in a research note on Friday, February 24th. Finally, Benchmark upgraded shares of NeoGenomics from a hold rating to a buy rating and set a $20.00 target price for the company in a research note on Friday, February 24th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, NeoGenomics has an average rating of Moderate Buy and an average price target of $19.33.

NeoGenomics Price Performance

NASDAQ NEO opened at $18.14 on Thursday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 6.46 and a current ratio of 6.73. The firm’s 50 day moving average price is $13.87 and its 200-day moving average price is $10.97. NeoGenomics has a 52-week low of $6.00 and a 52-week high of $19.51. The company has a market cap of $2.31 billion, a PE ratio of -15.64 and a beta of 1.13.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NEO. Bayesian Capital Management LP purchased a new position in shares of NeoGenomics during the third quarter worth $120,000. Edgestream Partners L.P. purchased a new position in shares of NeoGenomics during the third quarter worth $1,786,000. Security Benefit Life Insurance Co. KS purchased a new position in shares of NeoGenomics during the second quarter worth $44,000. Tudor Investment Corp Et Al purchased a new position in shares of NeoGenomics during the third quarter worth $477,000. Finally, Emerald Advisers LLC raised its holdings in shares of NeoGenomics by 76.3% during the third quarter. Emerald Advisers LLC now owns 2,139,579 shares of the medical research company’s stock worth $18,422,000 after purchasing an additional 926,226 shares during the last quarter. Hedge funds and other institutional investors own 88.15% of the company’s stock.

NeoGenomics Company Profile

(Get Rating)

NeoGenomics, Inc is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups.

Further Reading

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.